ENTITY
Ascletis Pharma

Ascletis Pharma (1672 HK)

112
Analysis
Health Care • China
Ascletis Pharma is a fully integrated biotechnology company focused on the research, development, production, marketing, and sale of innovative pharmaceutical products. The company's marketed products include Ritonavir tablets, GANOVO®, and ASCLEVIR® for Hepatitis C, and it has a robust pipeline primarily in metabolic diseases, viral diseases, and oncology. Ascletis Pharma is headquartered in Hangzhou, China, and was founded in 2011.
more
bearish•Haidilao
•02 Oct 2018 06:08

Last Week in GER Research: Haidilao, Popflops, Bitmain, Shandong Gold, Niu and China Renaissance

Below is a recap of the key IPO research produced by the Global Equity Research team. This week we highlight 25% potential downside at Haidilao as...

Logo
575 Views
Share
•28 Sep 2018 09:18

China Renaissance (华兴资本) Trading Update - Trading in Line with CICC

China Renaissance Holdings (1911 HK) raised US$345m at HK$31.80 per share, at the low-end of its range. We covered the IPO in our earlier insight,...

Share
bearish•Meituan
•24 Sep 2018 06:21

Last Week in GER Research: Meituan, IPO Trading Strategy, Shandong Gold, Maoyan and Viomi

Below is a recap of the key IPO research produced by the Global Equity Research team. This week we highlight that Meituan is closer to fair value...

Logo
440 Views
Share
bearish•Meituan
•17 Sep 2018 06:37

Last Week in GER Research: Meituan, Nio, Haidilao, Shandong Gold, China Renais., X Financial and PDD

Below is a recap of the key IPO research produced by the Global Equity Research team. This week we dig into the economics of Mobike as it relates...

Logo
478 Views
Share
bearish•Haidilao
•11 Sep 2018 12:03

Haidilao (6862 HK) IPO: Know When to Say No

Haidilao (6862 HK) announced the price range on Monday morning, coming to market at $10 - $12b through the range.  The nearly $1b dollar range is...

Share
x